EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pacific Hospital Supply Co Ltd (4126) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Pacific Hospital Supply Co Ltd TWD 95.42, price TWD 77.90, upside +22.5%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · TW · ISIN TW0004126008

PH Broad data Sep 24, 2026

Pacific Hospital Supply Co Ltd

4126 · TWO

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value 95.42 TWD · Undervalued (+22%)
✓Quality 74/100
✓Healthy Growth (revenue 5y +2.1 %/yr)
✓Solidly profitable · 14.9% net margin (TTM)
✓Low debt · generates free cash flow
·5.78% dividend yield
✓Ranks above peers (12/14)
!Moderate moat 61/100
!Insider activity 40/100

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

88.36 TWD 49.06 TWD Fair Value 95.42 TWD Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 49.06 TWD – 88.36 TWD · fair‑value band 66.79 TWD – 124.04 TWD · the 77.90 TWD price screens below the 95.42 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Pacific Hospital Supply Co in your weekly email

Every Wednesday you see whether Pacific Hospital Supply Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pacific Hospital Supply Co., Ltd., together with its subsidiaries, manufactures, processes, and sells medical devices in Taiwan.

Show more

Pacific Hospital Supply Co., Ltd., together with its subsidiaries, manufactures, processes, and sells medical devices in Taiwan. The company offers tubings, bags, bottles, closed wound drainage systems, surgical suction instruments, and other products, as well as involved in construction, installation, manufacturing, and sales of equipment piping and devices for medical gases. Its products in used for critical care/ward, general surgical, wound drainage, respiratory therapy/anesthesia, equipment protective cover, pediatric care, and medical gas system. The company also exports its products to approximately 80 countries and regions. Pacific Hospital Supply Co., Ltd. was founded in 1977 and is headquartered in Taipei, Taiwan.

Stock analysis

Pacific Hospital Supply Co Ltd (4126) currently trades at 77.90 TWD, while our model-based Fair Value estimate is 95.42 TWD, implying the stock looks roughly 18.4% undervalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of 96.13 TWD per share, and 16 of the 25 models we run sit above the 77.90 TWD price.

Bear case: the Asset-Based group reads lowest at 27.39 TWD, and 9 of the 25 models stay below the price. Evidence for this calculation is high.

Scenario range: 66.79 TWD (bear) to 124.04 TWD (bull), the price of 77.90 TWD sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Pacific Hospital Supply Co Ltd reported revenue of 2.4B TWD in FY2025 versus 2.0B TWD in FY2021, a compound +4.5%/yr. Reported net income was 383M TWD in FY2025, compounding −0.2%/yr from FY2021.

Key figures

Market cap 5.7B TWD (≈ $178M) · P/E ratio 14.9 · P/S ratio 2.37 · EPS (TTM) 5.24 TWD · Dividend yield 5.8% · Net margin 15.9% · Return on equity 11.5% · Return on assets (EBIT) 12.4%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 8% below its 52-week high and 5% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at 22%, 4126 screens cheaper than that median.

Fair Value models

Bear 66.79 TWD Fair Value 95.42 TWD Bull 124.04 TWD
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (0.5413 TWD per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 62.28 TWD 78.39 TWD 97.31 TWD 82
Growth DCF 62.75 TWD 77.15 TWD 93.26 TWD 80
Owner Earnings 60.04 TWD 75.44 TWD 93.53 TWD 78
All 25 models by family
DCF Models
FCF DCF 62.28 TWD 78.39 TWD 97.31 TWD 82
Owner Earnings 60.04 TWD 75.44 TWD 93.53 TWD 78
5Y Revenue Exit 64.78 TWD 91.05 TWD 123.37 TWD 73
5Y EBITDA Exit 76.78 TWD 112.56 TWD 152.68 TWD 76
5Y P/E Exit 76.06 TWD 111.26 TWD 146.55 TWD 71
10Y Revenue Exit 61.81 TWD 82.74 TWD 108.61 TWD 68
10Y EBITDA Exit 69.52 TWD 95.22 TWD 126.99 TWD 69
10Y P/E Exit 69.13 TWD 94.47 TWD 123.14 TWD 65
Earnings-Based
Graham-Dodd 35.86 TWD 89.52 TWD 116.13 TWD 65
PEG = 1.0 16.35 TWD 23.36 TWD 30.37 TWD 57
EPV 47.64 TWD 52.00 TWD 55.53 TWD 74
Dividend Discount
Gordon GGM 34.83 TWD 54.56 TWD 73.03 TWD 68
DDM Multi-Stage 34.83 TWD 48.11 TWD 59.70 TWD 67
Multiples
P/E Multiple 87.02 TWD 116.02 TWD 145.03 TWD 63
P/S Multiple 67.24 TWD 89.65 TWD 112.07 TWD 58
P/B Multiple 67.24 TWD 89.65 TWD 112.07 TWD 55
EV/EBIT 94.50 TWD 122.21 TWD 149.92 TWD 66
EV/EBITDA 99.90 TWD 129.40 TWD 158.91 TWD 67
EV/Revenue 70.71 TWD 96.13 TWD 121.56 TWD 54
Asset-Based
NCAV (Graham) 20.44 TWD 27.39 TWD 40.87 TWD 54
Growth DCF
Growth DCF 62.75 TWD 77.15 TWD 93.26 TWD 80
Rev-Margin DCF 64.78 TWD 91.71 TWD 121.05 TWD 73
Economic Profit
Residual Income 35.26 TWD 39.31 TWD 50.89 TWD 76
ROIC Compounder 48.39 TWD 54.32 TWD 60.35 TWD 72
Growth Earnings
Growth-Adj P/E 66.79 TWD 95.42 TWD 124.04 TWD 67

Open the full fair value analysis →

Notify me when 4126 reaches fair value

Put 4126 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 74/100

Of which business quality 73 · Market factors (momentum, volatility) 54

Profitability 52
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Cashflow 76
Earnings quality: real cash, not paper profit
Fin. Strength 94
Balance sheet, leverage, solvency risk
Investment 88
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 38
Price trend over the last 3–12 months (market factor)
52W Momentum 29
Distance to the 52-week high (market factor)
Net Issuance 83
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 67/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+2.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.1%
Start year 2020 (pandemic). Over 10 years: +4.0% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.8%
What shareholders gained per year (last 5 years), in TWD ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in TWD: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+5.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.1%
Dividend (yield on the price)5.8%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.0% vs 2%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.20% → 20%
Start year 2020 (pandemic)

Growth Forecast

Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+1.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about −0.2% a year for the price.

Watch 4126, get fair value alerts →

Compare Pacific Hospital Supply Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 74 · Top 25%
Fair Value upside +23% · Top 25%
Profitability
Return on equity (TTM) 12% · Above median
Return on assets 7% · Top 25%
Net margin (TTM) 15% · Top 25%
Operating margin (TTM) 20% · Top 25%
Growth and dividend
Revenue growth −4% · Bottom 25%
Dividend yield (TTM) 5.8% · Top 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (TTM) 14.9× · Cheapest 25%
P/B 1.91× · Pricier than median
P/S (TTM) 2.37× · Cheaper than median
P/FCF 0.4× · Cheapest 25%
EV/EBITDA 8.4× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)63 · sector 15
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)46 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)100 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.09 $353.38 −12%
EssilorLuxottica Société anonyme EL €144.50 €158.95 +10%
Medline Inc MDLN $34.43 $30.15 −12%
Becton, Dickinson and Company BDX $183.00 $103.53 −43%
Alcon Inc ALC $65.59 $39.78 −39%
ResMed Inc RMD A$31.61 A$34.77 +10%
West Pharmaceutical Services, Inc WST $371.09 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €206.40 €54.82 −73%
Straumann Holding STMN CHF 97.86 CHF 45.50 −54%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Pacific Hospital Supply Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/4126

Frequently asked questions

Is Pacific Hospital Supply Co Ltd (4126) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 95.42 TWD versus a price of 77.90 TWD, about +22% upside (undervalued).
What is the fair value of 4126?
Our model-based fair value for Pacific Hospital Supply Co Ltd is 95.42 TWD (as of Sep 24, 2026), built from audited fundamentals. The current price: 77.90 TWD.
What is the quality score of 4126?
Pacific Hospital Supply Co Ltd has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pacific Hospital Supply Co Ltd (4126)?
Our model-based price target is the fair value of 95.42 TWD (as of Sep 24, 2026) from 25 valuation models. Cautious scenario 66.79 TWD, optimistic scenario 124.04 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Pacific Hospital Supply Co Ltd stock forecast for 2026?
Our models put fair value at 95.42 TWD, about +22% upside versus a price of 77.90 TWD (undervalued). Cautious scenario 66.79 TWD, optimistic scenario 124.04 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Pacific Hospital Supply Co Ltd (4126)?
Pacific Hospital Supply Co Ltd reported trailing-twelve-month revenue of about 2.4B TWD (latest available figure, as of Sep 24, 2026).
Does Pacific Hospital Supply Co Ltd pay a dividend?
Pacific Hospital Supply Co Ltd currently shows a dividend yield of about 5.78% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Pacific Hospital Supply Co Ltd (4126)?
For today's price to be fair in a discounted-cash-flow model, Pacific Hospital Supply Co Ltd would have to grow free cash flow by +1.4 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +2.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 4126 use?
Our models discount Pacific Hospital Supply Co Ltd at 11.8 %: a base by market capitalisation (micro), damped by beta 0.11, country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pacific Hospital Supply Co Ltd that is +1.4 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Pacific Hospital Supply Co Ltd (4126) delivered so far?
Over the past 5 years revenue at Pacific Hospital Supply Co Ltd grew +2.1 % a year. The price currently implies +1.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pacific Hospital Supply Co Ltd (4126) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Pacific Hospital Supply Co Ltd (+1.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pacific Hospital Supply Co Ltd (4126)?
The free-cash-flow yield on the price is 8.15 %: that much free cash flow Pacific Hospital Supply Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pacific Hospital Supply Co Ltd (4126)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pacific Hospital Supply Co Ltd it is 95.42 TWD per share (as of Sep 24, 2026), against a price of 77.90 TWD. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Pacific Hospital Supply Co Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 4126 trades below its calculated fair value: price 77.90 TWD, fair value 95.42 TWD, a gap of about +22% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4126?
No. The price is what the market pays today (77.90 TWD); the fair value is what the company's own numbers justify (95.42 TWD). For Pacific Hospital Supply Co Ltd the two are 17.52 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Pacific Hospital Supply Co Ltd worth?
The market values Pacific Hospital Supply Co Ltd at about 5.7B TWD (market capitalisation, as of Sep 24, 2026). Per share that is 77.90 TWD; our models calculate a fair value of 95.42 TWD per share.
What do the bullish and bearish scenarios say about 4126?
Our models span a range for Pacific Hospital Supply Co Ltd: cautious scenario 66.79 TWD, base 95.42 TWD, optimistic 124.04 TWD per share (as of Sep 24, 2026, price 77.90 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4126?
Pacific Hospital Supply Co Ltd trades at a price-to-earnings ratio of 14.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 95.42 TWD is built from several models across several years. Other multiples: P/B 1.9, P/S 2.4, EV/EBITDA 8.4.
How solid is the balance sheet of Pacific Hospital Supply Co Ltd (4126)?
Balance-sheet figures for Pacific Hospital Supply Co Ltd (as of Sep 24, 2026): return on equity 11.5%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 4126 from its 52-week high?
Pacific Hospital Supply Co Ltd trades at 77.90 TWD, about 8% below its 52-week high of 84.64 TWD and 5% above the low of 74.06 TWD (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 95.42 TWD is for.
Which stocks are comparable to Pacific Hospital Supply Co Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pacific Hospital Supply Co Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 77.90 TWD, calculated fair value 95.42 TWD (+22%), Quality Score 74/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4126 calculated?
We run Pacific Hospital Supply Co Ltd through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 95.42 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Pacific Hospital Supply Co Ltd currently trades 22 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pacific Hospital Supply Co Ltd (4126)?
The closing price on Sep 23, 2026 was 77.90 TWD. Our model-based fair value is 95.42 TWD, about +22% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pacific Hospital Supply Co Ltd right now?
A fairly wide model range (66.79 TWD to 124.04 TWD) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Pacific Hospital Supply Co Ltd (4126) come from?
Earnings per share at Pacific Hospital Supply Co Ltd grew +1.9 % a year from 2012 to 2023. Broken into its drivers: revenue per share +4.5 %, EBIT margin −1.8 %, tax rate −0.2 %, residual (interest, one-offs) −0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Pacific Hospital Supply Co Ltd

How large is the market capitalisation of Pacific Hospital Supply Co Ltd (4126)?
The market capitalisation of Pacific Hospital Supply Co Ltd is 5.7B TWD (≈ $178M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pacific Hospital Supply Co Ltd (4126)?
The price-to-sales ratio of Pacific Hospital Supply Co Ltd is 2.37 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pacific Hospital Supply Co Ltd (4126)?
Earnings per share at Pacific Hospital Supply Co Ltd are 5.24 TWD (price ÷ EPS = P/E 14.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pacific Hospital Supply Co Ltd (4126)?
The dividend yield of Pacific Hospital Supply Co Ltd is 5.8% (payout 85.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pacific Hospital Supply Co Ltd (4126)?
The net margin of Pacific Hospital Supply Co Ltd is 15.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pacific Hospital Supply Co Ltd (4126)?
The return on equity (ROE) of Pacific Hospital Supply Co Ltd is 11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pacific Hospital Supply Co Ltd (4126)?
On an EBIT basis the return on assets of Pacific Hospital Supply Co Ltd is 12.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pacific Hospital Supply Co Ltd (4126)?
The operating margin of Pacific Hospital Supply Co Ltd is 20.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pacific Hospital Supply Co Ltd (4126)?
Revenue at Pacific Hospital Supply Co Ltd is growing −3.8% versus a year earlier (3y avg +3.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pacific Hospital Supply Co Ltd (4126)?
Earnings per share at Pacific Hospital Supply Co Ltd are growing −21.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Pacific Hospital Supply Co Ltd (4126) hold?
Pacific Hospital Supply Co Ltd holds more cash than debt, 308M TWD net (fiscal year 2023). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Pacific Hospital Supply Co Ltd in the live analysis

One click puts Pacific Hospital Supply Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.